March 5, 2007 Here’s an interesting new inhaler that provides metered dose inhaler (MDI) users with breath-activated delivery and dose-counting capabilities. From Accentia Biopharmaceuticals, the MD Turbo offers significant advantages for the users of many of the 40 million MDIs prescribed each year in the United States alone. Studies show that many patients using traditional press-and-breathe pMDIs (pressurized metered dose inhalers) to control asthma or Chronic Obstructive Pulmonary Disease (COPD), regardless of age or MDI experience, cannot successfully coordinate the press-and-breathe action necessary for drug delivery to the lungs. More than 70% of MDI users do not know the number of doses remaining in their inhalers at a given time.
See the stories that matter in your inbox every morning